TALVEY

all catalysts(0)

nothing on the calendar yet

News(4)

• Legend Biotech CEO abruptly steps down without permanent replacement
  In a sudden leadership shift, Legend Biotech announced that its CEO, Ying Huang, Ph.D., resigned on Friday, with no permanent replacement yet named.
  fiercebiotech · 19d ago
• Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
  Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.
  biopharma_dive · 21d ago
• J&J multiple myeloma drug gains edge in earlier stage disease
  The latest results studying Talvey in combination with Darzalex Faspro support J&J’s efforts to expand the immunotherapy's use.
  biopharma_dive · 2mo ago
• Dr Silbermann on Clinical Trial Design Considerations in Multiple Myeloma
  Rebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.
  onclive · 3mo ago